Algenex is a private biotech company at the forefront of transforming protein production. With its proprietary and patented technologies, Algenex is revolutionizing the production of recombinant proteins using BVES in insect cells. As a leading European biotech brand, Algenex offers a range of products and services across multiple sectors.

In the field of Animal Health, Algenex has over 20 years of experience in developing and producing animal vaccines. Through collaborations with public and private partners, they have successfully produced 200 molecules, including the first vaccine produced in their CrisBio® platform, FatrovaxRHD. Building on their expertise in animal health, Algenex is also expanding into Human Health, aiming to unlock the full potential of their technology platforms to produce proteins for medical purposes.

Additionally, Algenex has established itself as a producer of antigens proteins for diagnostic and therapeutic markets. Their patented technology platform, CrisBio®, has proven its applicability in the on-demand production of growth factors, enzymes, cytokines, and more. As a recognized industry leader, Algenex's proprietary technologies have gained support and recognition from various entities.

With their commitment to transforming protein production, Algenex aims to make biologics universally accessible